DNA repair defects in colon cancer

Current Opinion in Genetics and Development

Volumn 13, Issue 1, 2003, Pages 61-69

  Jiricny, Josef ^a   Marra, Giancarlo ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; POLYDEOXYRIBONUCLEOTIDE SYNTHASE;

CANCER; CARCINOGENESIS; COLON CANCER; DNA DAMAGE; DNA METABOLISM; DNA MODIFICATION; DNA REPAIR; EXCISION REPAIR; GENE MUTATION; HUMAN; MAMMAL; METHYLATION; MISMATCH REPAIR; NONHUMAN; PRIORITY JOURNAL; REVIEW;

MAMMALIA;

EID: 0037307925     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-437X(03)00004-2     Document Type: Review

References (80)

1. Friedberg EC, Walker GC, Siede W: DNA repair and mutagenesis. Washington, D.C.: ASM Press; 1995.
2. Jiricny J., Nyström-Lahti M. Mismatch repair defects in cancer. Curr. Opin. Genet Dev. 10:2000;157-161.
3. Aquilina G., Bignami M. Mismatch repair in correction of replication errors and processing of DNA damage. J. Cell Physiol. 187:2001;145-154.
4. Fishel R. The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: revising the mutator hypothesis. Cancer Res. 61:2001;7369-7374.
5. Peltomaki P. DNA mismatch repair and cancer. Mutat. Res. 488:2001;77-85.
6. Jass J.R., Whitehall V.L., Young J., Leggett B.A. Emerging concepts in colorectal neoplasia. Gastroenterology. 123:2002;862-876.
7. Herman J., Umar A., Polyak K., Graff J., Ahuja N., Issa J., Markowitz S., Willson J., Hamilton S., Kinzler K.et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc. Natl. Acad. Sci. U.S.A. 95:1998;6870-6875.
8. Sedgwick B., Lindahl T. Recent progress on the Ada response for inducible repair of DNA alkylation damage. Oncogene. 21:2002;8886-8894.
9. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene. 21:2002;5427-5440.
10. Slupska M.M., Baikalov C., Luther W.M., Chiang J.H., Wei Y.F., Miller J.H. Cloning and sequencing a human homolog (hMYH) of the Escherichia coli mutY gene whose function is required for the repair of oxidative DNA damage. J. Bacteriol. 178:1996;3885-3892.
11. Al-Tassan N., Chmiel N.H., Maynard J., Fleming N., Livingston A.L., Williams G.T., Hodges A.K., Davies D.R., David S.S., Sampson J.R.et al. Inherited variants of MYH associated with somatic G: C→T: A mutations in colorectal tumors Nat. Genet. 30:2002;227-232 Describes the identification of a compound heterozygous mutation in the MYH gene in three affected members of a multiple colorectal adenoma syndrome family.
12. ••], the authors identified seven further unrelated patients with >100 colorectal adenomas with biallelic germline mutations in MYH. The colorectal tumours from affected individuals displayed a significant excess of somatic G: C→T: A mutations in the APC gene. These findings confirm the role of MYH in colorectal adenoma and carcinoma predisposition.
13. Hendrich B., Hardeland U., Ng H.H., Jiricny J., Bird A. The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sites. Nature. 401:1999;301-304.
14. •] describe the identification of the thymine/uracil DNA-glycosylase activity of MBD4 (MED1). These studies showed that the enzyme consisted of two domains, methylated DNA binding domain and an endonuclease domain, both of which are functional. These findings implicated MBD4 (MED1) in the processing of G/T mispairs arising through the deamination of 5-methylcytosine.
15. Min/- mouse) leads to a substantial increase in the frequency of polyps that is linked to an increase in C to T transition mutations in the Apc gene. This confirms that MBD4 is indeed responsible for the repair of G/T mispairs arising through 5-methylcytosine deamination and links these events to polyp formation through the mutation of the Apc tumor suppressor gene.
16. Wong E., Yang K., Kuraguchi M., Werling U., Avdievich E., Fan K., Fazzari M., Jin B., Brown A.M., Lipkin M.et al. Mbd4 inactivation increases. C→T transition mutations and promotes gastrointestinal tumor formation Proc. Natl. Acad. Sci. U.S.A. 99:2002;14937-14942.
17. Hsieh P. Molecular mechanisms of DNA mismatch repair. Mutat. Res. 486:2001;71-87.
18. de Wind N., Dekker M., Claij N., Jansen L., Klink Y., Radman M., Riggins G., Valk M., van't Wout K., Riele H. HNPCC-like cancer predisposition in mice through simultaneous loss of msh3 and msh6 mismatch-repair protein functions. Nat. Genet. 23:1999;359-362.
19. Kuraguchi M., Yang K., Wong E., Avdievich E., Fan K., Kolodner R.D., Lipkin M., Brown A.M., Kucherlapati R., Edelmann W. The distinct spectra of tumor-associated Apc mutations in mismatch repair-deficient Apc1638N mice define the roles of MSH3 and MSH6 in DNA repair and intestinal tumorigenesis. Cancer Res. 61:2001;7934-7942 Shows that the wt copy of the Apc gene in MMR-deficient animals is inactivated by mutations rather than the usual LOH. This work demonstrates that the mode of inactivation of the Apc tumor suppressor gene in MMR-deficient tumors is different from the mode observed in sporadic tumors.
20. Raschle M., Marra G., Nystrom-Lahti M., Schar P., Jiricny J. Identification of hMutLβ, a heterodimer of hMLH1 and hPMS1. J. Biol. Chem. 274:1999;32368-32375.
21. Prolla T.A., Baker S.M., Harris A.C., Tsao J.L., Yao X., Bronner C.E., Zheng B., Gordon M., Reneker J., Arnheim N.et al. Tumor susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair. Nat. Genet. 18:1998;276-279.
22. •]).
23. Flores-Rozas H., Kolodner R.D. The Saccharomyces cerevisiae MLH3 gene functions in MSH3-dependent suppression of frameshift mutations. Proc. Natl. Acad. Sci. U.S.A. 95:1998;12404-12409.
24. Lipkin S.M., Moens P.B., Wang V., Lenzi M., Shanmugarajah D., Gilgeous A., Thomas J., Cheng J., Touchman J.W., Green E.D.et al. Meiotic arrest and aneuploidy in MLH3-deficient mice. Nat. Genet. 31:2002;385-390 Demonstration of the involvement of Mlh3 in meiosis rather than DNA repair.
25. Lipkin S.M., Wang V., Stoler D.L., Anderson G.R., Kirsch I., Hadley D., Lynch H.T., Collins F.S. Germline and somatic mutation analyses in the DNA mismatch repair gene MLH3: Evidence for somatic mutation in colorectal cancers. Hum. Mutat. 17:2001;389-396.
26. Yao X., Buermeyer A.B., Narayanan L., Tran D., Baker S.M., Prolla T.A., Glazer P.M., Liskay R.M., Arnheim N. Different mutator phenotypes in Mlh1- versus Pms2-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 96:1999;6850-6855.
27. Genschel J., Bazemore L.R., Modrich P. Human exonuclease I is required for 5′ and 3′ mismatch repair. J. Biol. Chem. 277:2002;13302-13311 Demonstration of the requirement for EXO1 in human cell-free MMR. Interestingly, the polypeptide, rather than its enzymatic activity, appeared to be required for 3′ to 5′ repair.
28. Wu Y., Berends M.J., Post J.G., Mensink R.G., Verlind E., Van Der Sluis T., Kempinga C., Sijmons R.H., van der Zee A.G., Hollema H.et al. Germline mutations of EXO1 gene in patients with hereditary nonpolyposis colorectal cancer (HNPCC) and atypical HNPCC forms. Gastroenterology. 120:2001;1580-1587.
29. Gazzoli I., Loda M., Garber J., Syngal S., Kolodner R.D. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res. 62:2002;3925-3928 The authors describe the identification of an HNPCC patient who appeared to be free of mutations in the MMR genes. However, one allele of hMLH1 was shown to be silenced by methylation in his lymphocytes, and the tumor appeared to have lost the wild type hMLH1 allele.
30. Grady W.M., Markowitz S.D. Genetic and epigenetic alterations in colon cancer. Annu. Rev. Genomics. Hum. Genet. 3:2002;101-128.
31. Lettieri T., Marra G., Aquilina G., Bignami M., Crompton N.E., Palombo F., Jiricny J. Effect of hMSH6 cDNA expression on the phenotype of mismatch repair-deficient colon cancer cell line HCT15. Carcinogenesis. 20:1999;373-382.
32. 2/M checkpoint triggered by DNA damage requires more MMR protein molecules to signal to the apoptotic machinery.
33. Qin X., Shibata D., Gerson S.L. Heterozygous DNA mismatch repair gene PMS2-knockout mice are susceptible to intestinal tumor induction with N-methyl-N-nitrosourea. Carcinogenesis. 21:2000;833-838.
34. Fishel R. Signaling mismatch repair in cancer. Nat. Med. 5:1999;1239-1241.
35. 2 cell cycle checkpoint. Cancer Res. 55:1995;3721-3725.
36. Adamson A.W., Kim W.J., Shangary S., Baskaran R., Brown K.D. ATM is activated in response to N-methyl-N′-nitro-N-nitrosoguanidine-induced DNA alkylation. J. Biol. Chem. 277:2002;38222-38229.
37. Brown KD, Rathi A, Beardsley DI, Zhan Q, Mannino JL, Baskaran R: The mismatch repair system is required for S-phase checkpoint activation. Nature Genet 2002, in press.
38. Fritzell J.A., Narayanan L., Baker S.M., Bronner C.E., Andrew S.E., Prolla T.A., Bradley A., Jirik F.R., Liskay R.M., Glazer P.M. Role of DNA mismatch repair in the cytotoxicity of ionizing radiation. Cancer Res. 57:1997;5143-5147.
39. •]).
40. Karran P., Bignami M. Drug-related killings: a case of mistaken identity. Chem. Biol. 3:1996;875-879.
41. Danson S.J., Middleton M.R. Temozolomide: a novel oral alkylating agent. Expert Rev. Anticancer Ther. 1:2001;13-19.
42. Mitra G., Pauly G.T., Kumar R., Pei G.K., Hughes S.H., Moschel R.C., Barbacid M. Molecular analysis of O6-substituted guanine-induced mutagenesis of ras oncogenes. Proc. Natl. Acad. Sci. U.S.A. 86:1989;8650-8654.
43. Esteller M., Toyota M., Sanchez-Cespedes M., Capella G., Peinado M.A., Watkins D.N., Issa J.P., Sidransky D., Baylin S.B., Herman J.G. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 60:2000;2368-2371.
44. •] describe cytosine methylation-induced silencing of the MGMT promoter in human malignancy and demonstrate the mutagenic effects of this event on two important genes, p53 and K-ras.
45. Kawate H., Itoh R., Sakumi K., Nakabeppu Y., Tsuzuki T., Ide F., Ishikawa T., Noda T., Nawata H., Sekiguchi M. A defect in a single allele of the Mlh1 gene causes dissociation of the killing and tumorigenic actions of an alkylating carcinogen in methyltransferase-deficient mice. Carcinogenesis. 21:2000;301-305.
46. Tomlinson I., Halford S., Aaltonen L., Hawkins N., Ward R. Does MSI-low exist? J. Pathol. 197:2002;6-13.
47. Wilson S.H. Mammalian base excision repair and DNA polymerase β Mutat. Res. 407:1998;203-215.
48. Klungland A., Rosewell I., Hollenbach S., Larsen E., Daly G., Epe B., Seeberg E., Lindahl T., Barnes D.E. Accumulation of premutagenic DNA lesions in mice defective in removal of oxidative base damage. Proc. Natl. Acad. Sci. U.S.A. 96:1999;13300-13305.
49. Minowa O., Arai T., Hirano M., Monden Y., Nakai S., Fukuda M., Itoh M., Takano H., Hippou Y., Aburatani H.et al. Mmh/Ogg1 gene inactivation results in accumulation of 8-hydroxyguanine in mice. Proc. Natl. Acad. Sci. U.S.A. 97:2000;4156-4161.
50. Nilsen H., Haushalter K.A., Robins P., Barnes D.E., Verdine G.L., Lindahl T. Excision of deaminated cytosine from the vertebrate genome: role of the SMUG1 uracil-DNA glycosylase. EMBO J. 20:2001;4278-4286.
51. Morland I., Rolseth V., Luna L., Rognes T., Bjoras M., Seeberg E. Human DNA glycosylases of the bacterial Fpg/MutM superfamily: an alternative pathway for the repair of 8-oxoguanine and other oxidation products in DNA. Nucleic Acids Res. 30:2002;4926-4936.
52. Wiebauer K., Jiricny J. Mismatch-specific thymine DNA glycosylase and DNA polymerase β mediate the correction of G.T mispairs in nuclear extracts from human cells. Proc. Natl. Acad. Sci. U.S.A. 87:1990;5842-5845.
53. Neddermann P., Gallinari P., Lettieri T., Schmid D., Truong O., Hsuan J.J., Wiebauer K., Jiricny J. Cloning and expression of human G/T mismatch-specific thymine-DNA glycosylase. J. Biol. Chem. 271:1996;12767-12774.
54. Bellacosa A., Cicchillitti L., Schepis F., Riccio A., Yeung A.T., Matsumoto Y., Golemis E.A., Genuardi M., Neri G. MED1, a novel human methyl-CpG-binding endonuclease, interacts with DNA mismatch repair protein MLH1. Proc. Natl. Acad. Sci. U.S.A. 96:1999;3969-3974.
55. Riccio A., Aaltonen L.A., Godwin A.K., Loukola A., Percesepe A., Salovaara R., Masciullo V., Genuardi M., Paravatou-Petsotas M., Bassi D.E.et al. The DNA repair gene MBD4 (MED1) is mutated in human carcinomas with microsatellite instability. Nat. Genet. 23:1999;266-268.
56. Scharer O.D., Jiricny J. Recent progress in the biology, chemistry and structural biology of DNA glycosylases. Bioessays. 23:2001;270-281.
57. Boldogh I., Milligan D., Lee M.S., Bassett H., Lloyd R.S., McCullough A.K. hMYH cell cycle-dependent expression, subcellular localization and association with replication foci: evidence suggesting replication- coupled repair of adenine: 8-oxoguanine mispairs. Nucleic Acids Res. 29:2001;2802-2809.
58. Gu Y., Parker A., Wilson T.M., Bai H., Chang D.Y., Lu A.L. Human MutY homolog, a DNA glycosylase involved in base excision repair, physically and functionally interacts with mismatch repair proteins human MutS homolog 2/human MutS homolog 6. J. Biol. Chem. 277:2002;11135-11142.
59. Gayet J., Zhou X.P., Duval A., Rolland S., Hoang J.M., Cottu P., Hamelin R. Extensive characterization of genetic alterations in a series of human colorectal cancer cell lines. Oncogene. 20:2001;5025-5032.
60. Rowan A.J., Lamlum H., Ilyas M., Wheeler J., Straub J., Papadopoulou A., Bicknell D., Bodmer W.F., Tomlinson I.P. APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'. Proc. Natl. Acad. Sci. U.S.A. 97:2000;3352-3357.
61. Ma A.H., Xia L., Littman S.J., Swinler S., Lader G., Polinkovsky A., Olechnowicz J., Kasturi L., Lutterbaugh J., Modrich P.et al. Somatic mutation of hPMS2 as a possible cause of sporadic human colon cancer with microsatellite instability. Oncogene. 19:2000;2249-2256.
62. de Wind N., Dekker M., Berns A., Radman M., te Riele H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell. 82:1995;321-330.
63. de Wind N., Dekker M., van Rossum A., van der Valk M., te Riele H. Mouse models for hereditary nonpolyposis colorectal cancer. Cancer Res. 58:1998;248-255.
64. Reitmair A.H., Schmits R., Ewel A., Bapat B., Redston M., Mitri A., Waterhouse P., Mittrucker H.W., Wakeham A., Liu B.et al. MSH2-deficient mice are viable and susceptible to lymphoid tumors. Nat. Genet. 11:1995;64-70.
65. Edelmann W., Yang K., Umar A., Heyer J., Lau K., Fan K., Liedtke W., Cohen P.E., Kane M.F., Lipford J.R.et al. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell. 91:1997;467-477.
66. Edelmann W., Umar A., Yang K., Heyer J., Kucherlapati M., Lia M., Kneitz B., Avdievich E., Fan K., Wong E.et al. The DNA mismatch repair genes Msh3 and Msh6 cooperate in intestinal tumor suppression. Cancer Res. 60:2000;803-807.
67. Kneitz B., Cohen P.E., Avdievich E., Zhu L., Kane M.F., Hou H. Jr., Kolodner R.D., Kucherlapati R., Pollard J.W., Edelmann W. MutS homolog 4 localization to meiotic chromosomes is required for chromosome pairing during meiosis in male and female mice. Genes Dev. 14:2000;1085-1097.
68. Edelmann W., Cohen P.E., Kneitz B., Winand N., Lia M., Heyer J., Kolodner R., Pollard J.W., Kucherlapati R. Mammalian MutS homologue 5 is required for chromosome pairing in meiosis. Nat. Genet. 21:1999;123-127.
69. Baker S.M., Plug A.W., Prolla T.A., Bronner C.E., Harris A.C., Yao X., Christie D.M., Monell C., Arnheim N., Bradley A.et al. Involvement of mouse Mlh1 in DNA mismatch repair and meiotic crossing over. Nat. Genet. 13:1996;336-342.
70. Edelmann W., Cohen P.E., Kane M., Lau K., Morrow B., Bennett S., Umar A., Kunkel T., Cattoretti G., Chaganti R.et al. Meiotic pachytene arrest in MLH1-deficient mice. Cell. 85:1996;1125-1134.
71. Kawate H., Sakumi K., Tsuzuki T., Nakatsuru Y., Ishikawa T., Takahashi S., Takano H., Noda T., Sekiguchi M.et al. Separation of killing and tumorigenic effects of an alkylating agent in mice defective in two of the DNA repair genes. Proc. Natl. Acad. Sci. U.S.A. 95:1998;5116-5120.
72. Edelmann W., Yang K., Kuraguchi M., Heyer J., Lia M., Kneitz B., Fan K., Brown A.M., Lipkin M., Kucherlapati R. Tumorigenesis in Mlh1 and Mlh1/Apc1638N mutant mice. Cancer Res. 59:1999;1301-1307.
73. Baker S.M., Bronner C.E., Zhang L., Plug A.W., Robatzek M., Warren G., Elliott E.A., Yu J., Ashley T., Arnheim N.et al. Male mice defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis. Cell. 82:1995;309-319.
74. Shoemaker A.R., Haigis K.M., Baker S.M., Dudley S., Liskay R.M., Dove W.F. Mlh1 deficiency enhances several phenotypes of Apc(Min)/+ mice. Oncogene. 19:2000;2774-2779.
75. Reitmair A.H., Cai J.C., Bjerknes M., Redston M., Cheng H., Pind M.T., Hay K., Mitri A., Bapat B.V., Mak T.W.et al. MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis. Cancer Res. 56:1996;2922-2926.
76. -/-; Min mice. Cancer Res. 58:1998;1087-1089.
77. Smits R., Hofland N., Edelmann W., Geugien M., Jagmohan-Changur S., Albuquerque C., Breukel C., Kucherlapati R., Kielman M.F., Fodde R. Somatic Apc mutations are selected upon their capacity to inactivate the β-catenin downregulating activity. Genes Chromosomes Cancer. 29:2000;229-239.
78. Cranston A., Bocker T., Reitmair A., Palazzo J., Wilson T., Mak T., Fishel R. Female embryonic lethality in mice nullizygous for both Msh2 and p53. Nat. Genet. 17:1997;114-118.
79. Toft N.J., Arends M.J., Wyllie A.H., Clarke A.R. No female embryonic lethality in mice nullizygous for Msh2 and p53, [letter; comment]. Nat. Genet. 18:1998;17.
80. +/- mice. Cancer Res. 62:2002;5134-5138.